Ritche Manos Hao, MD, BS
Assistant Professor of Medicine (Infectious DiseasesDownloadHi-Res Photo
Cards
Appointments
Infectious Diseases
Primary
Additional Titles
Medical Director, Information Technology-Physician Training, Yale New Haven Health System
Medical Information Officer, Information Technology, Yale New Haven Health System
Contact Info
Appointments
Infectious Diseases
Primary
Additional Titles
Medical Director, Information Technology-Physician Training, Yale New Haven Health System
Medical Information Officer, Information Technology, Yale New Haven Health System
Contact Info
Appointments
Infectious Diseases
Primary
Additional Titles
Medical Director, Information Technology-Physician Training, Yale New Haven Health System
Medical Information Officer, Information Technology, Yale New Haven Health System
Contact Info
About
Titles
Assistant Professor of Medicine (Infectious Diseases
Positions outside Yale
Medical Director, Information Technology-Physician Training, Yale New Haven Health System; Medical Information Officer, Information Technology, Yale New Haven Health System
Appointments
Infectious Diseases
Assistant ProfessorPrimaryBiomedical Informatics & Data Science
Assistant ProfessorSecondary
Other Departments & Organizations
Education & Training
- Fellowship
- University of Vermont (2006)
- Residency
- University of Connecticut Health Center (2004)
- Internship
- University of Connecticut (2002)
- Intern
- Philippine General Hospital (1999)
- MD
- University of Philippines, College of Medicine (1999)
- BS
- University of the Philippines Diliman, Psychology
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Ritche Manos Hao's published research.
Publications Timeline
A big-picture view of Ritche Manos Hao's research output by year.
Haddon Pantel, MD
Merceditas Villanueva, MD
Michael Virata, MD, FACP, FIDSA
Abhijeet Danve, MBBS, MD, MHS
Amit Achhra, MPH, PhD, MD
Andrew Esposito, MD
9Publications
20Citations
Publications
2024
Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings?
Palacios C, Chowdhary V, Hao R, Danve A, Malinis M. Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings? PLOS ONE 2024, 19: e0306337. PMID: 38959249, PMCID: PMC11221665, DOI: 10.1371/journal.pone.0306337.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsInterferon-gamma release assayDisease-modifying antirheumatic drugsInterferon-gamma release assay testLatent tuberculosis infectionNon-endemic settingsRheumatologic diseasesRisk factorsPositive interferon-gamma release assayLatent tuberculosis infection screeningLatent tuberculosis infection diagnosisPositive IGRA testMonths of rifampinLow-risk patientsRetrospective chart reviewTNF-alpha inhibitorsTB risk factorsTargeted LTBI screeningOutpatient rheumatology clinicDisease-modifying drugsIGRA testPatient demographicsAdult patientsChart reviewAntirheumatic drugsNon-endemic areas
2023
1478. Evaluation Of Anal Cancer Screening Program in men who have sex with men (MSM) persons with HIV (PWH) At Two academic center HIV Clinics 2018-2022
Achhra A, Chan E, Applebaum S, Guerrero M, Hao R, Pantel H, Virata M, Barakat L. 1478. Evaluation Of Anal Cancer Screening Program in men who have sex with men (MSM) persons with HIV (PWH) At Two academic center HIV Clinics 2018-2022. Open Forum Infectious Diseases 2023, 10: ofad500.1314. PMCID: PMC10677807, DOI: 10.1093/ofid/ofad500.1314.Peer-Reviewed Original ResearchConceptsAnal dysplasiaAbnormal PapHIV clinicAnal cancer screening programsAmbulatory HIV clinicRetrospective chart reviewHistory of smokingCancer screening programsSquamous cell carcinomaAnal cytologyAntiretroviral therapyHIV careChart reviewClinic visitsMedian ageMultivariable analysisCell carcinomaScreening programPrior historyAge 35High riskType of insuranceBackground treatmentCharacteristics of peoplePWHExpanded or Risk Factor-Based Annual Screening for Hepatitis C Virus (HCV) Among Persons With HIV: Which Is the Best Approach?
Hao R, Brooks R, Zelenev A, Spinner G, Barakat L, Villanueva M. Expanded or Risk Factor-Based Annual Screening for Hepatitis C Virus (HCV) Among Persons With HIV: Which Is the Best Approach? Health Promotion Practice 2023, 24: 1009-1017. PMID: 37439817, DOI: 10.1177/15248399231169794.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHepatitis C virusRisk factor-based screeningElectronic medical recordsHIV clinicAnnual screeningC virusRisk factorsScreening siteAnnual screening ratesNew HCV diagnosesClinical decision support toolRisk factor assessmentPublic health expertsHCV testingHCV casesClinical decision supportHCV diagnosisHCV testScreening ratesProspective studyMedical recordsPositivity ratePositive casesUnprotected sexClinic
2022
1897. The Decline of Respiratory Viruses During the SARS-CoV-2 Pandemic: Public Health Interventions vs. Viral Competition?
Malik W, Hao R, Shepherd J. 1897. The Decline of Respiratory Viruses During the SARS-CoV-2 Pandemic: Public Health Interventions vs. Viral Competition? Open Forum Infectious Diseases 2022, 9: ofac492.1524. DOI: 10.1093/ofid/ofac492.1524.Peer-Reviewed Original ResearchConceptsYale New Haven Health SystemSARS-CoV-2SARS-CoV-2 pandemicNon-pharmaceutical interventionsRespiratory virusesInfluenza A/BSARS-CoV-2 infectionSARS-CoV-2 testPositive RSV testRates of influenzaSeasonal respiratory virusesPublic health interventionsWeekly testsCOVID-19 databasePre-pandemic dataRSV testPre-pandemic levelsPositivity rateInfluenza APositive testNegative testSame periodHealth interventionsAge groupsRelaxation of NPIsDo Cultures From Percutaneously Drained Intra-abdominal Abscesses Change Treatment? A Retrospective Review
Esposito A, Zhang Y, Nagarkatti N, Laird W, Coppersmith N, Reddy V, Leeds I, Mongiu A, Longo W, Hao R, Pantel H. Do Cultures From Percutaneously Drained Intra-abdominal Abscesses Change Treatment? A Retrospective Review. Diseases Of The Colon & Rectum 2022, 66: 451-457. PMID: 36538708, DOI: 10.1097/dcr.0000000000002644.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsIntra-abdominal abscessPercutaneous drainAntimicrobial therapyLos pacientesAbdominal abscessSingle university-affiliated institutionRetrospective medical record reviewEmpiric antibiotic regimensSolid organ transplantsMedical record reviewUniversity-affiliated institutionCulture dataAntibiotic coursesAbdominal infectionAntibiotic regimensActive smokersMedian ageActive chemotherapyRecord reviewEvidence-based practiceMedian lengthUtility of cultureFemale sexIntraoperative culturesInclusion criteria
2018
Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients
Ogbuagu O, Hao R, Virata M, Villanueva MS, Malinis M. Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients. F1000Research 2018, 6: 620. PMID: 30344999, PMCID: PMC6171717, DOI: 10.12688/f1000research.11397.2.Peer-Reviewed Original ResearchCitationsConceptsHCV genotype 1 infectionGenotype 1 infectionHCV viral loadSOF/LDVViral loadSVR 12Treatment regimenGenotype 1Sustained virologic response 12 weeksYale New Haven Health SystemIU/HCV co-infected patientsVirologic response 12 weeksCo-infected patientsHCV treatment regimenMono-infected patientsSimilar viral loadsCompletion of therapyHCV genotype 1HIV viral loadSame treatment regimenSofosbuvir/ledipasvirStudy eligibility criteriaAntiretroviral therapyHCV infection
2017
Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients
Ogbuagu O, Hao R, Virata M, Villanueva M, Malinis M. Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients. F1000Research 2017, 6: 620. DOI: 10.12688/f1000research.11397.1.Peer-Reviewed Original ResearchCitationsConceptsHCV genotype 1 infectionGenotype 1 infectionHCV viral loadSOF/LDVViral loadSVR 12Treatment regimenGenotype 1Sustained virologic response 12 weeksYale New Haven Health SystemIU/HCV co-infected patientsVirologic response 12 weeksCo-infected patientsHCV treatment regimenMono-infected patientsSimilar viral loadsCompletion of therapyHCV genotype 1HIV viral loadSame treatment regimenSofosbuvir/ledipasvirStudy eligibility criteriaAntiretroviral therapyHCV infection
2013
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results
Kumar P, DeJesus E, Huhn G, Sloan L, Small CB, Edelstein H, Felizarta F, Hao R, Ross L, Stancil B, Pappa K, Ha B, for the SUPPORT Study Team. Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results. BMC Infectious Diseases 2013, 13: 269. PMID: 23741991, PMCID: PMC3685599, DOI: 10.1186/1471-2334-13-269.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdolescentAdultAgedAlkynesAnti-HIV AgentsBenzoxazinesBiomarkersC-Reactive ProteinCarbamatesCyclopropanesDideoxynucleosidesDrug CombinationsFemaleFibrin Fibrinogen Degradation ProductsFibrinogenFuransHIV InfectionsHumansInterleukin-6LamivudineMaleMiddle AgedOrganophosphatesPlasminogenProspective StudiesRitonavirSulfonamidesVascular Cell Adhesion Molecule-1Young AdultConceptsSoluble vascular adhesion molecule-1Fosamprenavir/ritonavirAbacavir/lamivudineAntiretroviral therapyD-dimerInterleukin-6Cardiovascular biomarkersWeek 96Hs-CRPWeek 4High-sensitivity C-reactive proteinInitiation of ARTTreatment-related grade 2HIV-1-infected populationVascular adhesion molecule-1Percentage of patientsTraditional risk factorsWeeks of treatmentC-reactive proteinHIV-1 RNAMajor resistance mutationsGeometric mean ratiosAdhesion molecule-1Backbone therapyEfavirenz 600
2010
SUPPORT: 48‐week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under‐represented, antiretroviral‐naïve patients
Kumar P, DeJesus E, Huhn G, Sloan L, Garcia F, Small C, Edelstein H, Felizarta F, Hao R, Ha B, Stancil B, Ross L, Oie K, Pappa K. SUPPORT: 48‐week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under‐represented, antiretroviral‐naïve patients. Journal Of The International AIDS Society 2010, 13: p7-p7. PMCID: PMC3113075, DOI: 10.1186/1758-2652-13-s4-p7.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
activity Yale New Haven Hospital EPIC Physician Builder Program
CommitteesMemberDetailsActive EPIC physician builder for YNHHS. Achievements include building HIV, TB, COVID-19 and Outpatient Parenteral Antibiotic Therapy synopsis views; documentation flowsheets for he NIDA drug screen tool, Latent tuberculosis. Building Bestpractice advisories eg hepatitis C risk based screening, research recruitment tool.2018 - Presentactivity EPIC Steering Board - Infectious Diseases
Advisory BoardsCommittee MemberDetailsEPICThis board is composed of Infectious Disease specialists from all over the country and meets monthly to review, discuss, and advise EPIC in regards to clinical tools and enhancements to their electronic medical record as it relates to the infectious disease subspecialty.2017 - Presentactivity American Academy of HIV Medicine HIV Credentialing Examination Test Writing
Professional OrganizationsVolunteerDetailsVolunteer HIV Certification Exam Test writer2019 - Presentactivity YNHH Inpatient EPIC Optimization Committee
CommitteesMemberDetailsThe committee reviews and approves EPIC builds for inpatient clinical care and workflows.2020 - Presentactivity Department of Internal Medicine Diversity Equity and Inclusion Committee, Yale School of Medicine
CommitteesMemberDetails07/01/2021 - Present
Clinical Care
Overview
Ritche Hao, MD, is an infectious diseases specialist who specializes in the care of patients with a variety of conditions, including HIV/AIDS, hepatitis C, prosthetic joint infection, osteomyelitis, and staphylococcus (staph) infection.
“The field of infectious diseases is always interesting and challenging at the same time,” says Dr. Hao. “The field of HIV care is fast evolving and the advances that have happened thus far give me hope that we are going to have a cure one day,” he says. In fact, he says, he is already able to help most of his patients who have HIV thrive and live normal lives.
Dr. Hao wants to tell his new patients, “I am here to help you.”
Clinical Specialties
Infectious Diseases; HIV & AIDs Medicine
Fact Sheets
Parasitic Diseases
Learn More on Yale MedicineMeningitis
Learn More on Yale MedicineClostridium difficile ( C. diff )
Learn More on Yale MedicinePneumonia
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
Events
Nov 202414Thursday
Everyone Brian L. Williams - Michael ConnollyUse link to join webinar. Passcode: 812090Yale Only Brian L. Williams - Michael ConnollyPlease click the link below to join the webinar: https://ynhh.zoom.us/j/95945390228?pwd=bnU0YW5QL1VJVVVCN1BCVkpldkVCZz09 Passcode: 812090